BioForce Nanosciences (BFNH) Stock Price, News & Analysis

Company Overview

BioForce Nanosciences, Inc. developed nanotechnology tools and systems for life-science and biotechnology applications. Its technology was designed to manipulate, deposit and analyze very small quantities of biological materials, supporting research in areas such as proteomics, genomics, diagnostics and drug discovery.

The company’s product portfolio included the Nano eNabler molecular printer, a platform intended to create precise arrays of proteins, DNA and other biomolecules on laboratory substrates. BioForce also developed related consumables, instruments and applications for nanoscale sample handling and bioanalytical research.

BioForce Nanosciences was historically based in Ames, Iowa, and served research institutions, biotechnology companies and pharmaceutical organizations. Publicly available information about the company’s current operations, leadership and geographic activities is limited.

Key Stats

• Today's Range: $7.74 to $8.45
• 50-Day Range: $2.81 to $10.01
• 52-Week Range: $0.18 to $10.99
• Volume: 5,631 shs
• Average Volume: 9,724 shs
• Market Capitalization: $294.66 million
• P/E Ratio: 774.77
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BioForce Nanosciences Stock Analysis - MarketRank™

BioForce Nanosciences scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioForce Nanosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioForce Nanosciences is 774.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 35.48.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioForce Nanosciences is 774.77, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 204.23.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of BioForce Nanosciences has been sold short.

Short Interest Ratio / Days to Cover

BioForce Nanosciences has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioForce Nanosciences has recently decreased by 67.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioForce Nanosciences does not currently pay a dividend.

Dividend Growth

BioForce Nanosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BioForce Nanosciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioForce Nanosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.54% of the stock of BioForce Nanosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

BioForce Nanosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BFNH
• CIK: 1310488
• Web: www.bioforceeclipse.com
• Phone: (757) 306-6090
• Fax: 757-306-6092
• Employees: 3
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: 774.77
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.67%
• Return on Assets: -16.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.41
• Quick Ratio: 25.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -387.00

Miscellaneous

• Outstanding Shares: 38,070,000
• Free Float: 23,015,000
• Market Cap: $294.66 million
• Optionable: Not Optionable
• Beta: 0.63